局限期小细胞肺癌不同治疗手段疗效与胃泌素释放肽前体及神经元特异性烯醇化酶水平的相关性研究  

Correlation study on the serum levels of ProGRP and NSE with different treatments in limiteddisease small cell lung cancer

作　　者：李晓敏[1] 李琦[1] 武亚娟[1] 任雅琼[1] 

机构地区：[1]山西省肿瘤医院放疗中心,太原030013

出　　处：《肿瘤研究与临床》2012年第11期735-737,741,共4页Cancer Research and Clinic

摘　　要：目的探讨不同治疗手段的局限期小细胞肺癌（SCLC）患者分别进行治疗前后血清胃泌素释放肽前体（ProGRP）和神经元特异性烯醇化酶（NSE）水平变化，并评价治疗效果与标志物血清水平的相关性。方法将150例局限期SCLC患者随机分为3个治疗组，即同步放化疗组、序贯放化疗组、单纯化疗组；应用酶联免疫吸附试验（ELISA）、电化学发光法对3组患者治疗前后ProGRP和NSE水平进行联合检测，并进行数据整理和分析。随访期为1年。结果3组患者ProGRP及NSE在治疗结束后均明显下降；其ProGRP与NSE的下降幅度依次为同步放化疗组、序贯放化疗组、单纯化疗组（318．96、250．77、226．18pg／ml及31．72、23．95、17．89μg／L）；三组按近期疗效好排序，依次为同步放化疗组、序贯放化疗组、单纯化疗组；同步放化疗组明显优于单纯化疗组，差异有统计学意义（P〈0．05）。在各组中，治疗有效的患者ProGRP与NSE的下降幅度明显大于治疗无效的患者；病情进展时，相应ProGRP与NSE上升，差异有统计学意义（P〈0．05）。结论ProGRP和NSE水平可反映出局限期SCLC患者的病情变化并可评估疗效；同步放化疗优于序贯放化疗和单纯化疗。Objective To study the correlation of the serum levels of pro-gastrin-releasing peptide （ProGRP） and neuro-specific enolase （NSE） with different treatments in limited-disease small cell lung cancer （L-SCLC） patients. Methods 150 L-SCLC patients were randomly divided into three groups including concurrent chemo-radiotherapy group, sequential chemo-radiotherapy group, and chemotherapy group. The serum levels of ProGRP and NSE were detected by enzyme-linked immunosorbent assay （ELISA） and electrochemiluminescence immunoassay before and after different treatments. The follow-up phase was 12 months. Results The serum levels of ProGRP and NSE were significantly decreased in all 3 groups after treatment （318.96, 250.77, 226.18 pg/ml and 31.72, 23.95, 17.89 μg/L）, and the lowest level was observed in concurrent chemo-radiotherapy group, then the sequential chemo-radiotherapy group and chemotherapy group. The short term therapeutic effects were in the same sequence, and there was statistical significance between concurrent chemoradiotherapy group and chemotherapy （P 〈 0.05）. The decrease extent of ProGRP and NSE in effective cases （CR＋PR） was significantly higher than that in failure Cases in all 3 groups. The serum levels of ProGRP and NSE were increased with disease progress （P 〈 0.05）. Conclusion The serum levels of ProGRP and NSE can be used to reflect the patient＇ s condition and evaluate therapeutic effect in L-SCLC. The concurrent chemo-radiotherapy is more effective than sequential chemo-radiotherapy and chemotherapy only in L-SCLC.

关 键 词：癌 小细胞肺 胃泌素释放肽前体 神经元特异性烯醇化酶 疗效 

分 类 号：R734.2[医药卫生—肿瘤]